GEN Exclusives

More »

GEN News Highlights

More »
Jan 22, 2008

Microbix to Manufacture and Investigate Development of ImaRx Compound

  • ImaRx Therapeutics and Microbix Biosystems signed a letter of intent related to the manufacture and further development of urokinase. The product is currently marketed under the brand name Abbokinase® as a a thrombolytic drug.

    ImaRx intends to transfer the manufacturing process and NDA to Microbix to create a new source for urokinase. Microbix has the right to develop the compound for certain indications in catheter clearance and prophylaxis of serious catheter related complications such as blood stream infections and venous thrombi. Microbix’ also expects to investigate the candidates potential in oncology and ophthalmology.

    ImaRx will retain existing drug inventory and exclusive rights to sell the drug as a thrombolytic agent. It will gain access to a long-term drug supply from Microbix. ImaRx will also pursue development of urokinase for indications other than those signed over to Microbix. Additionally, ImaRx will receive royalties on sales of urokinase for new indications developed by Microbix.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »